The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.
Market Growth Overview
- Recent Growth: The opioid-induced constipation (OIC) treatment market has seen significant growth, increasing from $1.66 billion in 2023 to $1.78 billion in 2024, with a CAGR of 6.7%.
- Future Projections: Expected to grow to $2.31 billion by 2028 at a CAGR of 6.8%, driven by several factors.
Key Drivers in the Historic Period
- Expanding Geriatric Population: Older adults are more likely to use opioids, leading to higher instances of OIC.
- Personalized Treatments: Tailored OIC treatments have become more available, enhancing effectiveness.
- Effective OIC Drugs: Increased availability of drugs specifically targeting OIC.
- Prevalence of Opioid Use: Rising opioid prescriptions contribute to the need for OIC treatments.
- Gastrointestinal Disorders: A higher incidence of gastrointestinal issues boosts the demand for OIC therapies.
Drivers for Future Growth
- Accelerated Drug Approval: Faster approval processes for new drugs.
- Opioid Analgesic Prescriptions: Increasing use of opioids for pain management.
- R&D Expenditure: Significant investments in research and development for novel treatments.
- Development of Biologics: Advances in biologic treatments for OIC.
Read More On The Opioid-Induced Constipation Treatment Market Report 2024 – https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report
Emerging Trends
- Patient Education: Increased efforts in educating patients about OIC and its treatments.
- Targeted Therapies: Development of therapies specifically targeting OIC mechanisms.
- Non-pharmacological interventions: Exploration of alternative treatments beyond medications.
- Biotechnology Innovations: Cutting-edge biotech solutions for managing OIC.
- Increased Investment: More financial resources directed towards OIC treatment advancements.
Rising Opioid Use for Pain Management
- Cancer and Non-Cancer Pain: Opioids are widely used for managing both cancer-related and non-cancer pain.
- Quality of Life: Effective OIC treatments improve patient comfort and adherence to pain management regimens without compromising pain relief.
- Statistics: According to the CDC, 20.9% of U.S. adults reported chronic pain in 2021, highlighting the need for OIC treatments.
Major Players in the Market
- Companies: Key players include Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, and many others.
Developments in OIC Treatments
- Mu-Opioid Receptor Antagonists: Companies are focusing on these antagonists to manage OIC effectively.
- Notable Approval: In December 2021, Shionogi & Co. Ltd. received approval for Symproic (naldemedine) in Taiwan, expanding treatment options.
Grünenthal and Kyowa Kirin Joint Venture
- Collaboration: In August 2023, Grünenthal GmbH and Kyowa Kirin International formed a joint venture to market pain management and OIC medications.
- Focus Areas: The collaboration includes a range of products, emphasizing OIC and pain management.
Market Segmentation
- By Drug Class: Includes laxatives, peripherally acting µ-opioid receptor antagonists, serotonin receptor agonists, and prostaglandin.
- By Type: Oral and parenteral treatments.
- By Distribution Channel: Hospital pharmacies, online pharmacies, and retail pharmacies.
Regional Insights
- North America: Largest market in 2023.
- Asia-Pacific: Expected to be the fastest-growing region during the forecast period.
The opioid-induced constipation treatment market is poised for continued growth, driven by increasing opioid use, advancements in treatment options, and significant investments in R&D. With major players innovating and forming strategic collaborations, the market is set to expand, offering improved solutions for patients suffering from OIC.
Request for A Sample Of The Global Opioid-Induced Constipation Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=15881&type=smp